ENTX Receives FDA Feedback
Entera Bio receives FDA's positive feedback for its Phase 3 registrational protocol for EB613 tablet to treat osteoporosis
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
ENTX Receives FDA Feedback
ENTX - Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis